SCHEMBL7185752

SCHEMBL7185752

CC(=O)OC1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3cc(C#N)ccc32)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CCR2 P41597 1/20 0.42
C5AR1 P21730 2/20 0.39
OPRM1 P35372 1/20 0.37
USP2 O75604 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.37
CLPP Q16740 1/20 0.37
MEN1 O00255 1/20 0.37
ALOX15 P16050 1/20 0.37
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
CASP7 P55210 1/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
DRD4 P21917 2/20 0.36
KDM4E B2RXH2 1/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185745 1.00 CYP3A4 (0.44) CYP3A4CYP2D6CCR2C5AR1OPRM1
SCHEMBL7188239 0.91 CYP3A4 (0.40) CYP3A4CYP2D6CCR2OPRM1MAPT
SCHEMBL7188245 0.91 CYP3A4 (0.40) CYP3A4CYP2D6CCR2OPRM1MAPT
SCHEMBL7176913 0.87 CYP3A4 (0.47) CYP3A4CYP2D6CCR2C5AR1OPRM1
SCHEMBL7176915 0.87 CYP3A4 (0.47) CYP3A4CYP2D6CCR2C5AR1OPRM1
SCHEMBL7190835 0.86 PDE7A (0.42) PRMT5WDR77DRD4
SCHEMBL7190841 0.86 PDE7A (0.42) PRMT5WDR77DRD4
SCHEMBL7179404 0.85 C5AR1 (0.47) CYP3A4CYP2D6C5AR1OPRM1HPGD
SCHEMBL7179410 0.85 C5AR1 (0.47) CYP3A4CYP2D6C5AR1OPRM1HPGD
SCHEMBL7190418 0.84 PDE7A (0.49) C5AR1PRMT5WDR77KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed